Breast cancer remains a leading cause of cancer-related mortality worldwide, with metastasis representing the most formidable challenge in clinical management. Among metastatic sites, the liver is notorious for harboring secondary tumors that are often resistant to existing therapies. Understanding the molecular drivers that enable breast cancer cells to colonize the liver is therefore crucial. This study identifies MSLN, or mesothelin, as a pivotal mediator in this process, orchestrating intracellular signaling events that promote tumor spread and survival in hepatic tissue.

MSLN is a glycoprotein normally expressed in mesothelial cells but is aberrantly overexpressed in several malignancies, including pancreatic and ovarian cancer. Its role in breast cancer metastasis has been less clear until now. The research team, led by Dr. Jiang Chen and colleagues, deployed an integrative approach combining patient-derived samples, in vitro cellular models, and in vivo metastasis assays to dissect MSLN’s functional contributions.

Their findings establish that overexpressed MSLN on breast cancer cells acts as an initiator of the EGFR-ERK1/2 signaling cascade. EGFR (epidermal growth factor receptor) is a well-characterized receptor tyrosine kinase implicated in various oncogenic processes. Activation of EGFR triggers downstream ERK1/2 kinases (extracellular signal-regulated kinases), which ultimately regulate gene transcription programs conducive to proliferation, migration, and survival.

The study demonstrated through biochemical assays that MSLN physically interacts with EGFR on the cancer cell surface, enhancing EGFR phosphorylation and subsequent ERK1/2 pathway activation. This crosstalk creates a positive feedback loop that sustains aggressive cellular phenotypes. Disrupting this interaction using targeted inhibitors or genetic silencing of MSLN markedly reduced ERK1/2 activation, curtailing the metastatic capacity of breast cancer cells.

Importantly, animal models of breast cancer metastasis validated these molecular insights. Mice engrafted with breast cancer cells exhibiting high MSLN expression exhibited significantly increased liver metastasis, as revealed by histopathology and bioluminescent imaging. Conversely, blockade of MSLN or downstream signals suppressed metastatic lesion formation, highlighting potential strategic points for intervention.

On a clinical front, the researchers analyzed tumor biopsies from breast cancer patients with known metastatic status. Patients with liver metastases showed elevated MSLN levels and heightened EGFR-ERK1/2 signaling components compared to non-metastatic cases, indicating the clinical relevance of this axis. Such biomarkers could improve prognosis predictions and personalize patient therapies targeting this pathway.

This discovery advances the conceptual framework of how tumor cells adapt to distinct microenvironments during metastasis. The liver microenvironment is rich in growth factors and stromal elements that appear to synergize with MSLN-driven signaling, supporting colonization and outgrowth. Future studies might explore how MSLN modulates interactions with hepatic cellular constituents, potentially unveiling additional targets.

Therapeutically, the study suggests a two-pronged approach: designing agents to inhibit MSLN directly and employing EGFR-ERK1/2 pathway inhibitors more effectively in metastatic breast cancer. Current EGFR inhibitors have faced resistance issues; the findings imply that combination strategies targeting the upstream MSLN could circumvent resistance and improve patient outcomes.

Moreover, the mechanistic clarity provided by this research paves the way for developing diagnostic tests measuring circulating MSLN or related signaling proteins as liquid biopsy markers. Early detection of metastatic propensity could revolutionize follow-up care, shifting the clinical paradigm toward proactive management.

The significance of this work extends beyond breast cancer. Given MSLN’s expression in multiple tumor types, similar mechanisms may underpin metastasis in other malignancies. Thus, the insights generated hold broad implications for oncology, inspiring cross-cancer studies and novel drug discovery efforts.

This study represents a prime example of translational research, moving from molecular biology to animal models and human samples, offering a comprehensive view of cancer metastasis biology. Such integrative studies are vital for tackling the complexity of cancer dissemination, ultimately aiming to reduce the heavy burden of metastatic diseases.

In summary, the elucidation of MSLN-mediated activation of EGFR-ERK1/2 signaling as a driving force for liver metastasis in breast cancer marks a momentous advance. It highlights a previously underappreciated signaling axis that could serve as a linchpin for future diagnostics and therapeutics. As research progresses, targeting the MSLN-EGFR-ERK1/2 pathway may become a cornerstone in the fight against deadly metastatic breast cancer.

This discovery did not happen in isolation; it builds upon decades of cancer signaling research yet uniquely clarifies the metastatic niche specificity to the liver. Understanding why cancer cells metastasize to certain organs remains a fundamental question, and studies like this shine light on the molecular determinants, providing hope for tailored and effective treatments.

The potential to “switch off” metastatic signaling by interfering with MSLN or its downstream effectors also stimulates interest in combination therapies that engage standard treatments with novel molecularly targeted drugs. This integrative approach could mitigate drug resistance, reduce metastasis, and ultimately improve survival rates for breast cancer patients worldwide.

Future efforts will need to focus on validating these findings in larger patient cohorts and clinical trials to translate laboratory insights into effective clinical therapies. Furthermore, the development of specific MSLN inhibitors or monoclonal antibodies suitable for human use will be pivotal steps toward clinical application.

As breast cancer remains a significant public health challenge, innovations addressing metastasis are essential. This study’s elucidation of a critical molecular driver behind liver metastasis inspires renewed vigor in the quest for curative interventions, signaling a hopeful horizon for patients and clinicians alike.

—

Subject of Research: Mechanistic investigation of MSLN-mediated activation of EGFR-ERK1/2 signaling pathway driving liver metastasis in breast cancer.

Article Title: MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer.

Article References:
Chen, J., Lu, Z., Zhang, G. et al. MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer. Cell Death Discov. 12, 11 (2026). https://doi.org/10.1038/s41420-025-02835-9

Image Credits: AI Generated

DOI: 09 January 2026

Emerging from this landscape, a groundbreaking study has brought to light a novel non-transcriptional regulator intricately involved in sustaining the plastic mesenchymal state characteristic of metastatic ovarian cancer cells. At the heart of this discovery is Dynamin 1 (DNM1), a GTPase classically known for its pivotal role in endocytosis. Using integrative bioinformatics analyses across The Cancer Genome Atlas (TCGA) datasets, encompassing a broad spectrum of over 8,000 patient samples from 20 cancer types, researchers employed advanced computational frameworks including master regulator algorithms and the Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNE). This comprehensive approach unveiled markedly elevated expression of DNM1 in ovarian cancer patients exhibiting advanced clinical stages and mesenchymal subtypes, with a compelling correlation to diminished progression-free and post-relapse survival, positioning DNM1 as a putative driver of tumor aggressiveness.

Functionally dissecting DNM1’s contribution, in vitro experiments delineated its crucial role in regulating EMT phenotypes. Silencing DNM1 expression in highly metastatic ovarian cancer cell lines resulted in a significant attenuation of mesenchymal traits—cells exhibited reduced migratory capacity and decreased expression of N-cadherin, a key adhesion molecule intimately linked to EMT and metastatic competence. Conversely, ectopic overexpression of DNM1 in otherwise non-metastatic ovarian cancer cells induced a pronounced acquisition of invasive characteristics, concomitant with upregulated N-cadherin. These functional modulations underscore the indispensable role of DNM1 in tuning the dynamic equilibrium between epithelial and mesenchymal states.

Validating these findings in vivo, murine models of peritoneal metastasis reinforced the functional indispensability of DNM1 in metastatic colonization. Mice bearing ovarian tumors with targeted DNM1 knockdown manifested a stark reduction in tumor dissemination across the peritoneum, corroborating the in vitro insights and implicating DNM1 as a formidable mediator of metastatic colonization. Delving deeper into mechanistic pathways, the research revealed that DNM1 orchestrates EMT progression by regulating the endocytic recycling of glycosylated N-cadherin. This post-translational trafficking mechanism sustains the plasticity and polarity of mesenchymal cancer cells, facilitating enhanced migratory and invasive capacities essential for metastasis.

Complementing these mechanistic insights, integrated epigenomic and transcriptomic analyses, harnessing ATAC-seq and RNA-seq technologies, unveiled a potential suppressive axis in non-metastatic ovarian cancer cells. The enzyme beta-1,3-galactosyltransferase 1 (B3GALT1) emerged as upregulated in such contexts, hypothesized to antagonize EMT by impeding the recycling of N-cadherin, thereby dampening mesenchymal plasticity. This finding not only delineates differential regulatory landscapes underpinning metastatic versus non-metastatic states but also suggests a complex interplay between glycosylation enzymes and endocytic trafficking in cancer progression.

Beyond molecular intricacies, the study illuminated surprising therapeutic implications relating to nanoparticle-mediated drug delivery. Metastatic ovarian cancer cells characterized by heightened DNM1 activity displayed increased sensitivity to nanoparticle uptake, attributed to their augmented endocytic machinery. This phenomenon hints at the tantalizing prospect of exploiting DNM1-mediated endocytosis to enhance the efficacy of nanodrugs, potentially ushering in a paradigm shift in targeted ovarian cancer therapies that transcends conventional approaches.

Taken together, these findings establish a previously unrecognized DNM1-N-cadherin axis as a fundamental regulator of EMT plasticity and metastatic virulence in ovarian cancer. By linking endocytic trafficking mechanisms to cellular phenotype regulation, the research bridges pivotal gaps in our understanding of metastatic biology. The identification of DNM1 as both a biomarker and mechanistic driver opens promising therapeutic avenues, including targeted nanodrug delivery strategies that capitalize on inherent cellular vulnerabilities.

This paradigm-shifting work, titled “Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis”, was published on April 9, 2025 in the journal Protein & Cell. It exemplifies how integrating multi-omic datasets with experimental rigor can unravel complex cancer biology, moving beyond traditional transcription factor-centric models toward novel non-transcriptional pathways with translational relevance.

Beyond expanding our molecular grasp of ovarian cancer metastasis, these insights may transcend this malignancy, as DNM1 and endocytic pathways are likely implicated in diverse tumor contexts exhibiting EMT-driven dissemination. Future research should prioritize the development of specific inhibitors targeting DNM1-mediated endocytic recycling and refine nanotherapeutic carriers tailored to exploit this pathway. Such innovations promise to significantly advance precision oncology, offering hope to patients grappling with aggressive and metastatic ovarian cancer.

Ultimately, this pioneering study underscores the transformative potential of targeting non-transcriptional regulators of EMT, particularly those involved in membrane trafficking and protein recycling, a frontier that until now has remained largely unexplored. By charting this novel territory, the research champions a new era of metastasis-targeted therapies with the potential to improve clinical outcomes for one of the most challenging cancers faced by modern medicine.

Article Title: Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis
News Publication Date: 9-Apr-2025
Web References: https://doi.org/10.1093/procel/pwaf019
Image Credits: Yuee Cai, Zhangyan Guan, Yin Tong, Weiyang Zhao, Jiangwen Zhang, Ling Peng, Philip P. C. Ip, Sally K. Y. To, Alice S. T. Wong
Keywords: Ovarian cancer, Epithelial-mesenchymal transition, Dynamin 1, Endocytic recycling, N-cadherin, Metastasis, Glycosylation, Nanoparticle uptake, Biomarker, Targeted therapy